ProPhase Labs reminds shareholders of upcoming special meeting

UNIONDALE, NY - ProPhase Labs, Inc. (NASDAQ:PRPH) has issued a reminder to shareholders about its Special Meeting of Stockholders scheduled for November 24, 2025, at 10:00 a.m. ET in Lynbrook, NY. The micro-cap company, currently trading at $0.28 per share with a market capitalization of just $11.63 million, has seen its stock decline by 63% year-to-date.

Shareholders of record as of October 20, 2025, are eligible to attend the meeting in person at 273 Merrick Road. The company emphasized the importance of voting before the proxy deadline of 11:59 p.m. ET on November 23, 2025.

The meeting will address proposals outlined in the company's definitive proxy statement filed with the Securities and Exchange Commission. The board of directors has recommended that shareholders vote in favor of all proposed resolutions.

According to the company, the proposals are designed to support ProPhase's strategic initiatives and maintain compliance with Nasdaq listing requirements. CEO Ted Karkus stated that the company anticipates "unveiling a very positive strategic initiative in the coming weeks."

ProPhase Labs noted that reaching quorum is essential for the meeting to proceed. The company warned that failure to vote for the proposals could potentially limit its ability to execute certain initiatives or delay actions that support its long-term vision.

Shareholders can vote online at proxyvote.com, by telephone, by mail, or in person at the meeting.

ProPhase Labs describes itself as a biotech, genomics and consumer products company with subsidiaries focused on whole genome sequencing, diagnostic development, and over-the-counter dietary supplements.

The information in this article is based on a company press release statement.

In other recent news, ProPhase Labs has announced significant developments across various aspects of its business. The company reported that its BE-Smart test for Barrett's Esophagus achieved 100% sensitivity in detecting patients who later developed esophageal cancer, as validated by a study conducted with Mayo Clinic and published in Clinical and Translational Gastroenterology. In a separate announcement, ProPhase Labs disclosed that its three COVID-19 testing subsidiaries have filed for Chapter 11 bankruptcy protection due to outstanding payments owed by insurance companies. This filing is limited to the COVID-19 lab units and does not involve the parent company or other business divisions.

Additionally, ProPhase Labs has entered into an agreement with ThinkEquity for a $6 million private placement, which is part of the company's digital asset treasury strategy. This agreement designates ThinkEquity as the exclusive strategic advisor and placement agent. The company is also exploring options for its balance sheet resources, including potential investments in digital assets, following shareholder approval at a recent Special Meeting. Furthermore, ProPhase Labs has terminated its equity line agreement with Keystone Capital Partners, which allowed the sale of common stock worth up to approximately $7.7 million. This termination was executed at the company's discretion without incurring penalties.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.